Watch - Sofosbuvir, ribavirin therapy after liver transplant shows positive results for HCV patients

Sofosbuvir, ribavirin therapy after liver transplant shows positive results for HCV patients

November 15, 2013

WASHINGTON — Combined sofosbuvir and ribavirin therapy to treat established recurrent hepatitis C infection after liver transplant has proven successful in preliminary results, according to research presented by Michael R. Charlton, MD, in a late-breaking abstract at The Liver Meeting.

The ongoing single-arm, open-label interferon-free pilot study enrolled 40 naive and treatment-experienced patients with recurrent HCV infection of any genotype after liver transplantation. The patients received up to 24 weeks of sofosbuvir and ribavirin with a primary endpoint of sustained virologic response 12 weeks after completion of treatment.

Full Story »